| Active substance | lenvatinib |
| Holder | Eisai |
| Status | closed |
| Indication | in combination with pembrolizumab for the treatment of patients with advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 02/09/2022 |